title: Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
abstract: BACKGROUND
  Pegylated interferon alfa-2a (40 KD) plus ribavirin therapy induces sustained virological response rates up to 63% in randomized-controlled trials.
  
  
  OBJECTIVE
  To conduct a prospective open-label programme to examine the efficacy and safety of this therapy in routine clinical practice.
  
  
  METHODS
  Treatment-naive patients with chronic hepatitis C received, at the discretion of the investigator, pegylated interferon alfa-2a 180 microg/week + ribavirin 800 mg/day for 24 or 48 weeks. In total, 508 patients were enrolled [334 non-cirrhotic; 174 cirrhotic (defined as stage F3 and F4)].
  
  
  RESULTS
  In genotype 1 patients treated for 48 weeks, sustained virological response rates were 41% in non-cirrhotics and 34% in cirrhotics. Sustained virological response rates in genotype 2 or 3 non-cirrhotics were 79% (24 weeks) and 72% (48 weeks). Corresponding values for cirrhotic genotype 2/3 were 66% and 44%. The negative predictive value of an early virological response at week 12 was 94%. Predictive factors for sustained virological response on multivariate analysis were genotype (2/3 vs. 1), low viral load and degree of fibrosis. Rates of serious adverse events (<or=5%) and adverse events inducing withdrawal (<or=8%) were comparable with the phase III trials.
  
  
  CONCLUSIONS
  Efficacy and safety of pegylated interferon alfa-2a + ribavirin in clinical practice is comparable with results of randomized-controlled trials.
authors.affiliation: Liver Unit, University of Calgary, Calgary, AB, Canada. samlee@ucalgary.ca
authors.forename: S S
authors.initials: SS
authors.lastname: Lee
authors.forename: V G
authors.initials: VG
authors.lastname: Bain
authors.forename: K
authors.initials: K
authors.lastname: Peltekian
authors.forename: M
authors.initials: M
authors.lastname: Krajden
authors.forename: E M
authors.initials: EM
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Deschenes
authors.forename: J
authors.initials: J
authors.lastname: Heathcote
authors.forename: R J
authors.initials: RJ
authors.lastname: Bailey
authors.forename: S
authors.initials: S
authors.lastname: Simonyi
authors.forename: M
authors.initials: M
authors.lastname: Sherman
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002170:Canada; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a